Deep Medicine Acquisition (Deep Medicine Acquisition) ROCE % : -28.16% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Deep Medicine Acquisition ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Deep Medicine Acquisition's annualized ROCE % for the quarter that ended in Sep. 2023 was -28.16%.

Deep Medicine Acquisition ROCE % Historical Data

The historical data trend for Deep Medicine Acquisition's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deep Medicine Acquisition ROCE % Chart

Deep Medicine Acquisition Annual Data

Trend

Mar21

Mar22

Mar23

ROCE %

-0.64

-3.20

Deep Medicine Acquisition Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial							-2.24	-2.45	-41.80	-21.72	-28.16

Deep Medicine Acquisition ROCE % Calculation

Deep Medicine Acquisition's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-2.167	/	( ( (128.953 - 0.537)	+	(9.777 - 2.795) )	/ 2 )
	=	-2.167	/	( (128.416	+	6.982)	/ 2 )
	=	-2.167	/	67.699
	=	-3.20 %

Deep Medicine Acquisition's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-1.444	/	( ( (10.013 - 3.293)	+	(7.005 - 3.47) )	/ 2 )
	=	-1.444	/	( ( 6.72	+	3.535 )	/ 2 )
	=	-1.444	/	5.1275
	=	-28.16 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Deep Medicine Acquisition (NAS:DMAQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Deep Medicine Acquisition ROCE % Related Terms

Thank you for viewing the detailed overview of Deep Medicine Acquisition's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Deep Medicine Acquisition (Deep Medicine Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Deep Medicine Acquisition Corp (NAS:DMAQ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

595 Madison Avenue, 12th Floor, New York, NY, USA, 10017

Website

Deep Medicine Acquisition Corp is a blank check company.

Executives

John Chiang	director	3538 TORRANCE BLVD., UNIT 177, TORRANCE CA 90503
Bryant Fong	director	2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Humphrey P Polanen	director, officer: Chief Executive Officer	C/O HERITAGE COMMERCE CORP, 150 ALMADEN BLVD, SAN JOSE CA 95113
Weixuan Luo	officer: Chief Financial Officer	40 WALL STREET, 29TH FLOOR, NEW YORK NY 10005
Marc Hamer	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Bright Vision Sponsor Llc	10 percent owner	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Ronald M. Razmi	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Hongliang Ren	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Wanlei Miao	director	595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017
Tina Spires	director	595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017